Form 8-K

8-K — Structure Therapeutics Inc.

Accession: 0001104659-26-043425

Filed: 2026-04-15

Period: 2026-04-15

CIK: 0001888886

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2611763d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2611763d1_ex99-1.htm)

GRAPHIC (tm2611763d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2611763d1_8k.htm · Sequence: 1

false

0001888886

True

0001888886

2026-04-15

0001888886

gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember

2026-04-15

0001888886

gpcr:OrdinarySharesParValue0.0001PerShareMember

2026-04-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

April 15, 2026

Structure

Therapeutics Inc.

(Exact name of registrant as specified in its

charter)

Cayman

Islands

001-41608

98-1480821

(State

or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

601

Gateway Blvd., Suite

900

South

San Francisco, California

94080

(Address

of principal executive offices)

(Zip

Code)

(Registrant’s

telephone number, including area code): (650)

457-1978

Not Applicable

(Former name or former address, if changed

since last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General

Instruction A.2. below):

Written communications pursuant

to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered

pursuant to Section 12(b) of the Act:

Title

of Each Class

Name Of Each Exchange

Trading Symbol(s)

On Which

Registered

American

Depositary Shares (ADSs), each representing three

ordinary shares, par value $0.0001 per ordinary share

GPCR

Nasdaq

Global Market

Ordinary

shares, par value $0.0001 per share*

True

Nasdaq

Global Market*

* Not for trading, but only in connection with the registration of

the American Depositary Shares

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging

growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any

new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Director or Certain

Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Matthew Lang was appointed as Structure

Therapeutics, Inc.’s (the “Company”) Chief Operating Officer and General Counsel, effective April 15, 2026.

Mr. Lang previously served as the Chief

Legal Officer and Corporate Secretary at Metsera, Inc. (“Metsera”), a biopharmaceutical

company, from April 2025 until February 2026 and prior to Metsera Mr. Lang served as Chief Business Officer and Chief Legal

Officer and Corporate Secretary of Lyell Immunopharma, Inc. (“Lyell”), a biotechnology company, from July 2023 to April

2025. Before joining Lyell, Mr. Lang held several executive officer positions at Myovant Sciences, Inc.

(“Myovant”), a biotechnology company, between 2017 and 2023, most recently as Chief Administrative and Legal Officer.

Mr. Lang also served as Managing Director and General Manager of Myovant Sciences GmbH in Basel, Switzerland. Mr. Lang

previously held leadership positions at Gilead Sciences, Inc. (“Gilead”), from November 2009 to July 2017, most recently as Vice President, Head of Global Litigation, Investigations, Employment Law and Information Governance.

Prior to Gilead, from 2003 to 2009, Mr. Lang was an attorney at Dechert LLP. Mr. Lang received his B.A. in Classical

Studies from Queen’s University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School.

Pursuant to the terms of Mr. Lang’s employment

agreement (the “Employment Agreement”), effective as of April 15, 2026, Mr. Lang will receive a base salary of $560,000 per year and be eligible for an annual discretionary

bonus with a target amount of 40% of his base salary based on the achievement of certain corporate and/or individual objectives and milestones

that are determined by the Board of Directors of the Company, with no pro-ration of any annual discretionary

bonus payout for 2026. Mr. Lang will be granted (i) an option to purchase 223,776 ordinary shares (representing 74,592 American Depositary

Shares (“ADSs”)), (ii) a time-based restricted share unit award (the “RSUs”) in respect of 184,614 ordinary shares

(representing 61,538 ADSs) and (iii) a performance-based restricted share unit award (the “PSUs”) in respect of 46,155 ordinary

shares (representing 15,385 ADSs) at target levels. Mr. Lang’s employment may be terminated at-will by either party, with or without notice.

One-fourth of the shares underlying Mr. Lang’s

option award will vest on the first anniversary of the vesting commencement date, and the remaining shares will vest in 36 equal monthly

installments thereafter, subject to Mr. Lang’s continuous service through each vesting date. The RSUs will vest over four years

with one-quarter vesting on the first anniversary of the vesting commencement date, and on each anniversary thereafter, subject to Mr.

Lang’s continuous service through each vesting date.

The PSUs will be allocated to three separate

tranches, each of which will vest based on the achievement of the applicable milestone, as follows: (i) vesting of 25% of the PSUs

will be based upon achievement of the first milestone by December 31, 2027, (ii) vesting of 25% of the PSUs will be based upon achievement

of the second milestone by September 30, 2028, and (iii) vesting of 50% of the PSUs will be based upon achievement of the third

milestone by June 30, 2029. For each tranche, depending on when the milestone is achieved during the performance period, the number

of PSUs that vest may be between 75% to 125% of the target number of PSUs. If the milestone for a tranche is not achieved during the

applicable performance period, none of the PSUs allocated to such tranche will vest. Any PSUs that become eligible to vest based on achievement

of the applicable milestone will vest on the date such achievement is certified, subject to Mr. Lang’s continuous service through

such date.

The foregoing description of the Employment Agreement

does not purport to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement which will

be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.

Mr. Lang will enter into the Company’s

standard form of indemnification agreement, a form of which was filed as Exhibit 10.1 to the Company’s Registration Statement on

Form S-1 (File No. 333-269200), filed with the Securities and Exchange Commission on January 12, 2023.

The selection of Mr. Lang to serve as the Company’s

Chief Operating Officer and General Counsel was not pursuant to any arrangement or understanding with respect to any other person. In

addition, there are no family relationships between Mr. Lang and any director or executive officer of the Company. Mr. Lang has not been

a party to any transaction with the Company or its subsidiaries of the type required to be disclosed pursuant to Item 404(a) of Regulation

S-K, and no such transaction is currently contemplated.

Item 7.01 Regulation FD Disclosure.

The Company issued a press

release announcing Mr. Lang’s appointment. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and

incorporated herein by reference. The information set forth in this Item 7.01 and in the

press release attached hereto as Exhibit 99.1, is deemed to be “furnished” and shall not be deemed to be “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject

to the liabilities of that Section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed

incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent that

the Company specifically incorporates it by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press Release

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Structure Therapeutics Inc.

Date: April 15, 2026

By:

/s/ Raymond Stevens

Raymond Stevens, Ph.D.

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2611763d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Structure Therapeutics Appoints Matthew Lang,

J.D.

as Chief Operating Officer and General Counsel

SAN FRANCISCO, April 14, 2026 – Structure Therapeutics

Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic

diseases, with a focus on obesity, today announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel.

Mr. Lang joins Structure Therapeutics with more than fifteen years of executive leadership experience across global biopharmaceutical

organizations, with deep expertise spanning legal, corporate strategy, compliance, risk management, and business development.

“Matt is a proven leader with a strong track record of guiding

organizations through growth and transformation,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “His experience

across global operations, strategic transactions, and commercialization will be critical as we move aleniglipron into Phase 3 and continue

to build a world-class leadership team.”

Mr. Lang most recently served as Chief Legal Officer and Secretary

at Metsera, Inc., helping to guide the company through its up to $10 billion acquisition by Pfizer. Prior to Metsera, Mr. Lang served

as Chief Business and Legal Officer at Lyell Immunopharma, Inc., and held several executive officer positions at Myovant Sciences, where

he helped lead the company through Phase 3 clinical development, global approval and commercialization of Myfembree® and Orgovyx®.

Mr. Lang also served as the Managing Director and General Manager of Myovant’s European operations in Basel Switzerland where he

was responsible for all aspects of Myovant’s ex-US business operations. Earlier in his career Mr. Lang held roles of increasing

seniority at Gilead Sciences, Inc., and was an attorney at Dechert, LLP. He received his B.A. in Classical Studies from Queen’s

University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School.

“I am excited to join Structure Therapeutics at this important

stage as we move into Phase 3 development with one of the most promising late-stage assets in the competitive obesity landscape,”

said Mr. Lang. “The Company’s mission and differentiated portfolio represent a compelling opportunity to deliver a complete

pipeline of meaningful therapies to patients. I look forward to working with the team to further strengthen the Company’s operational

foundation, execute on strategic priorities, and drive long-term value.”

About Structure Therapeutics

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral

small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based

drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage

oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible

to more people living with obesity around the world. For additional information, please visit www.structuretx.com.

Forward Looking Statements

This press release contains “forward-looking statements”

within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements

other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation,

statements concerning: the Company’s future plans and prospects; and any expectations regarding the potential benefits, tolerability

and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects and future application

of aleniglipron and any other of the Company’s investigational compounds. In addition, when or if used in this press release, the

words and phrases “anticipated,” “believe,” “expect,” “may,” “on track,” “plan,”

“potential,” “suggests,” “to be,” “to begin,” “will,” and similar expressions

and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical

facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements

are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results,

levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s

forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related

to potential delays in the commencement, enrollment and completion of the Company’s planned clinical studies; the Company’s

ability to advance aleniglipron, ACCG-2671, ACCG-3535, ANPA-0073, LTSE-2578, and its other therapeutic candidates, obtain regulatory approval

of, and ultimately commercialize the Company’s therapeutic candidates; competitive products or approaches limiting the commercial

value of the Company’s product candidates; the Company’s ability to fund development activities and achieve development goals;

and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission (SEC), including

the Company’s latest Annual Report on Form 10-K and future reports the Company may file with the SEC from time to time. All forward-looking

statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions

and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances

that exist after the date on which they were made, except as required by law.

Investors:

Corey Davis, Ph.D.

LifeSci Advisors, LLC

212-915-2577

cdavis@lifesciadvisors.com

Jun Yoon

Structure Therapeutics Inc.

ir@structuretx.com

Media:

Dan Budwick

1AB

Dan@1abmedia.com

#####

GRAPHIC

Filename: tm2611763d1_ex99-1img001.jpg · Sequence: 7

Binary file (23323 bytes)

Download tm2611763d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Apr. 15, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 15, 2026

Entity File Number

001-41608

Entity Registrant Name

Structure

Therapeutics Inc.

Entity Central Index Key

0001888886

Entity Tax Identification Number

98-1480821

Entity Incorporation, State or Country Code

Entity Address, Address Line One

601

Gateway Blvd.

Entity Address, Address Line Two

Suite

900

Entity Address, City or Town

South

San Francisco

Entity Address, State or Province

Entity Address, Postal Zip Code

94080

City Area Code

650

Local Phone Number

457-1978

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

American Depositary Shares Adss Each Representing Three Ordinary Shares Par Value 0. 0001 Per Ordinary Share [Member]

Title of 12(b) Security

American

Depositary Shares (ADSs), each representing three

ordinary shares, par value $0.0001 per ordinary share

Trading Symbol

GPCR

Security Exchange Name

NASDAQ

Ordinary Shares Par Value 0. 0001 Per Share [Member]

Title of 12(b) Security

Ordinary

shares, par value $0.0001 per share*

No Trading Symbol Flag

true

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true only for a security having no trading symbol.

+ References

No definition available.

+ Details

Name:

dei_NoTradingSymbolFlag

Namespace Prefix:

dei_

Data Type:

dei:trueItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=gpcr_AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=gpcr_OrdinarySharesParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: